Adjunctive therapies for sepsis and septic shock
The inflammatory cascade that ensues after an infectious insult is protean in its manifestations, resulting in mild self-limited illness in some patients, while progressing to fulminant sepsis and multisystem organ failure in others. Research into the pathophysiology of this cascade has been intense, but advances in the treatment of sepsis have been few and far between. Although mortality rates have been impacted slightly in patients with sepsis—with improved survival in certain patient subgroups—overall survival still reaches only 55% to 60%. In this paper we will review some of the most recent advances in the therapy of the sepsis syndrome, specifically the roles of cytokine modifiers, supranormal delivery of oxygen, granulocyte colony-stimulating factor administration in leukopenic patients, and parenteral nutrition. Hopefully, these modalities represent additional steps in the path towards a meaningful improvement in survival from this catastrophic condition.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 8.Abraham E, Anzueto A, Gutierrez G, et al.: Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998, 351:929–933. This follow-up to two earlier trials (which demonstrated some benefit with use of monoclonal antibody to TNF-a) showed no benefit on mortality in a large cohort of patients. Patients in the treatment arm did have a significantly decreased incidence of coagulopathy compared with placebo.PubMedGoogle Scholar
- 9.Reinhart K, Wiegand-Lohnert C, Grimminger F, et al.: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996, 24:733–742.PubMedCrossRefGoogle Scholar
- 11.Abraham E: Status report of soluble receptors in the treatment of septic shock [abstract]. In IBC Sixth Annual International Symposium on Sepsis. Boston, 1996.Google Scholar
- 18.Lauterbach R, Pawlik D, Kowalczyk D, et al.: Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999, 27:807–814. This study in premature infants demonstrated improved mortality in those infants with sepsis who received pentoxifylline 5 mg/kg/h for 6 hours on 6 consecutive days compared with placebo. There was also significantly less disordered peripheral circulation, metabolic acidosis, anuria or oliguria, disseminated intravascular coagulation, and necrotizing enterocolitis. The study correlated these findings with measurements of TNF and IL-6 concentrations that were significantly decreased in the treatment group.PubMedCrossRefGoogle Scholar
- 21.Hirasawa H, Sugai T, Oda S, et al.: Continuous hemodiafiltration can remove humoral mediators from the bloodstream of patients with SIRS/ MODS [abstract]. Blood Purif 1997, 15:136.Google Scholar
- 39.Alia I, Esteban A, Gordo F, et al.: A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock. Chest 1999, 115:453–461. This recent trial of supranormal oxygen delivery in 63 medicalsurgical intensive care unit patients showed no improvement in survival. However, only nine of 31 treatment patients reached the target oxygen delivery index of 600 mL/min/m2.PubMedCrossRefGoogle Scholar
- 44.Hartung T, Volk HD, Wendel A: G-CSF: an anti-inflammatory cytokine (abstract). Shock 1997, (suppl 1):81.Google Scholar
- 46.Nelson S, Farkas S, Fotheringham N, et al.: Filgrastim in the treatment of hospitalized patients with community acquired pneumonia (abstract). Am J Respir Crit Care Med 1996, 153:A535.Google Scholar
- 47.Ishikawa K, Tanaka H, Tetsuya M, et al.: Recombinant human G-CSF attenuates inflammatory responses in septic patients with neutropenia. J Trauma 1998, 44:1047–1054. Subcutaneous administration of G-CSF to patients with sepsis and total leukocyte counts less than 5000/mm3 led to significant increases in in vitro neutrophil function as well as improvement in APACHE II and Multiple Organ Failure index scores.PubMedCrossRefGoogle Scholar
- 48.Garcia-de-Lorenzo A, Ortiz-Leyba C, Planas M, et al.: Parenteral administration of different amounts of branch-chain amino acids in septic patients: clinical and metabolic aspects. Crit Care Med 1997, 25:418–424. Administration of 45% solutions of branch-chain amino acids versus standard concentrations of 23% branch-chain amino acids led to improved survival and increased concentrations of prealbumin and retinol-binding protein compared with controls.PubMedCrossRefGoogle Scholar